Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 December 2013Website:
http://www.xencor.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
XNCR Latest News
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will.
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.
Xencor (XNCR) has the optimal mix of factors for a potential earnings surpass in its upcoming report. Make sure you are ready with the essential expectations.
Xencor (XNCR) experienced a surge in stock price during the previous session with higher-than-average trading volume. However, recent changes in earnings estimates for the stock do not indicate continued strength in the future.
Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.
- 1(current)
What type of business is Xencor?
Xencor, Inc. is a biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics for the treatment of serious diseases (oncology, autoimmune). Founded in 1997. The company's main laboratory and administrative facilities are located in Monrovia, California. Xencor, Inc.'s patent portfolio includes over 1000 issued patents and pending patent applications. To carry out most of its operations and development programs, Xencor, Inc. relies on third-party contractors and service providers. Manufacturing, testing, quality assurance, clinical monitoring, data management, and regulatory expertise are outsourced to third parties.
What sector is Xencor in?
Xencor is in the Healthcare sector
What industry is Xencor in?
Xencor is in the Biotechnology industry
What country is Xencor from?
Xencor is headquartered in United States
When did Xencor go public?
Xencor initial public offering (IPO) was on 03 December 2013
What is Xencor website?
https://www.xencor.com
Is Xencor in the S&P 500?
No, Xencor is not included in the S&P 500 index
Is Xencor in the NASDAQ 100?
No, Xencor is not included in the NASDAQ 100 index
Is Xencor in the Dow Jones?
No, Xencor is not included in the Dow Jones index
When was Xencor the previous earnings report?
No data
When does Xencor earnings report?
The next expected earnings date for Xencor is 27 February 2025